

Confirmed Speakers

Plenary lectures

The Polarity of Drug Discovery: Targeted or Phenotypic?



Dr Hayley BINCH
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

Title to be announced



Dr Mark MURCKO
(DEWPOINT THERAPEUTICS, Boston, United States)

New Chemistries for the Preparation of DNA-Encoded Libraries

Recent Advances in DNA-encoded Library Technology at GSK



Dr Melissa GRENIER-DAVIES
(GLAXOSMITHKLINE, Cambridge, MA, United States)

Development of SAR-CoV-2 Mpro Inhibitors Using DNA-Encoded Chemical Libraries



Prof. Damian YOUNG
(BAYLOR COLLEGE OF MEDICINE, Houston, TX, United States)

Advances in Linkerology

Targeted Cancer Therapy with Best-in-Class Antibody-Drug Conjugates Based on Clinical-Stage GlycoConnect™ and HydraSpace Technologies



Dr Floris VAN DELFT
(SYNAFFIX, Oss, The Netherlands)

Recent Advances in Neurodegenerative Diseases

Discovery of a Potent and Brain Penetrant O-GlcNAcase (OGA) Inhibitor Able to Reduce Tau Pathology in a Preclinical Animal Model



Dr Peter BUIJNSTERS
(JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT, Beerse, Belgium)

In silico enabled discovery of KAI-11101, a DLK inhibitor for the treatment of neurodegenerative diseases



Dr H. Rachel LAGIAKOS
(SCHRODINGER, New York, NY, United States)

Hybrid Compounds for Neurodegenerative Diseases: from Small Molecules to Targeted Therapies

Confirmed Speakers



Dr Maria Joao MATOS
(UNIVERSITY OF SANTIAGO DE COMPOSTELA, Santiago de Compostela, Spain)

Fragment Based Drug Discovery

Title to be announced



Dr Johan VEERMAN
(ZOBIO BV, Leiden, The Netherlands)

Some Guidelines for SBDD



Dr Alison WOOLFORD
(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

Protein-protein Interactions

Title to be announced



Prof. Luc BRUNSVELD
(EINDHOVEN UNIVERSITY OF TECHNOLOGY, Eindhoven, The Netherlands)

From Protein Structures to Bioactive Proteomimetics



Prof. Tom GROSSMANN
(VU UNIVERSITY AMSTERDAM, Amsterdam, The Netherlands)

Emerging Synthetic Methodologies

From Molecules to Molecular Surfaces and Back Again. Exploiting the Synergy between Electrochemistry and Organic Synthesis



Prof. Kevin MOELLER
(WASHINGTON UNIVERSITY, Saint Louis, MO, United States)

Click Chemistry in the Discovery of a Modulator of the Store-Operated Calcium Entry for the Treatment for Rare Genetic Myopathies



Prof. Tracey PIRALI
(UNIVERSITY OF PIEMONTE ORIENTALE, Novara, Italy)

Targeting Immune Checkpoints with Small Molecules

Discovery of Quemiclistat, a Potent and Selective Small Molecule Inhibitor of CD73

Confirmed Speakers



Dr Jenna L. JEFFREY
(ARCUS BIOSCIENCES, Hayward, CA, United States)

Title to be announced



Dr Markus KLEIN
(MERCK KGAA, Darmstadt, Germany)

From RNA Targeting to Degraders and Beyond: Impact of Novel Modalities on Clinical Pipelines

Development of Orally Bioavailable Peptides Targeting an Intra-cellular Protein: From a Hit to a Clinical KRAS Inhibitor



Dr Ryuji HAYASHI
(CHUGAI PHARMACEUTICAL CO.,LTD., Kanagawa , Japan)

Targeted Protein Degradation Using Cereblon Molecular Glues



Dr Lyn H. JONES
(DANA FARBER CANCER INSTITUTE, Boston, MA, United States)

A Focus on Early Career Investigators

Antibody Discovery vs Challenging Proteins



Dr Francesco APRILE
(IMPERIAL COLLEGE LONDON, London, United Kingdom)

Dynamics and Mechanism of CRISPR-Cas9 through the Lens of Computational Methods.



Dr Giulia PALERMO
(UNIVERSITY OF CALIFORNIA RIVERSIDE, Riverside, United States)